Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P40259
UPID:
CD79B_HUMAN
Alternative names:
B-cell-specific glycoprotein B29; Ig-beta; Immunoglobulin-associated B29 protein
Alternative UPACC:
P40259; Q53FS2; Q9BU06
Background:
The B-cell antigen receptor complex-associated protein beta chain, also known as B-cell-specific glycoprotein B29, Ig-beta, or Immunoglobulin-associated B29 protein, plays a pivotal role in B-cell development. It is essential for the signal transduction cascade activated by the B-cell antigen receptor complex, leading to antigen presentation.
Therapeutic significance:
Agammaglobulinemia 6, an autosomal recessive condition characterized by severe infections due to low or absent serum antibodies and B-cells, is linked to mutations in this protein. Understanding its role could lead to novel treatments for primary immunodeficiencies.